Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at
Wall Street Ze
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]